» Articles » PMID: 34981417

Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy

Overview
Journal Mol Neurobiol
Date 2022 Jan 4
PMID 34981417
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance to temozolomide (TMZ) chemotherapy is the main reason for treatment failure in patients with glioblastoma (GBM). In the present study, we investigated biochanin A (BCA) a potent sensitizer of TMZ in GBM. We observed that BCA significantly enhanced cell sensitivity to TMZ in vitro and in vivo. Mechanistically, the specific chemosensitizing effect of BCA is mediated by autophagy inhibition. Moreover, by performing a molecular docking analysis, we demonstrated that BCA interacts with AMPK residues and impairs autophagy by regulating the AMPK/ULK1 pathway. These results suggest that BCA is a potential therapeutic agent that sensitizes GBM to TMZ and provide new insight into its therapeutic potential in chemoresistant GBM.

Citing Articles

A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules.

Afshari A, Sanati M, Aminyavari S, Keshavarzi Z, Ahmadi S, Oroojalian F Inflammopharmacology. 2025; .

PMID: 39955698 DOI: 10.1007/s10787-025-01666-5.


New Salicylanilide Derivatives and Their Peptide Conjugates as Anticancer Compounds: Synthesis, Characterization, and Effect on Glioblastoma.

Horvath L, Biri-Kovacs B, Baranyai Z, Stipsicz B, Mehes E, Jezso B ACS Omega. 2024; 9(15):16927-16948.

PMID: 38645331 PMC: 11024950. DOI: 10.1021/acsomega.3c05727.


New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy.

Majchrzak-Celinska A, Studzinska-Sroka E Molecules. 2024; 29(7).

PMID: 38611962 PMC: 11013944. DOI: 10.3390/molecules29071682.


Mechanisms Behind the Pharmacological Application of Biochanin-A: A review.

Anuranjana P, Beegum F, K P D, George K, Viswanatha G, Nayak P F1000Res. 2023; 12:107.

PMID: 38106650 PMC: 10725524. DOI: 10.12688/f1000research.126059.3.


Evaluation of flaxseed lignan-enriched extract targeting autophagy, apoptosis, and hedgehog pathways against experimentally induced obesity.

Khater S, Shalabi M, Alammash B, Alrais A, Al-Ahmadi D, Alqahtani L J Adv Vet Anim Res. 2023; 10(2):321-335.

PMID: 37534085 PMC: 10390674. DOI: 10.5455/javar.2023.j684.


References
1.
Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008; 88(1):97-103. DOI: 10.1007/s11060-008-9538-0. View

2.
Ma W, Jin H, Liu W, Li X, Zhou X, Guo X . Homeobox B8 Targets Sterile Alpha Motif Domain-Containing Protein 9 and Drives Glioma Progression. Neurosci Bull. 2019; 36(4):359-371. PMC: 7142204. DOI: 10.1007/s12264-019-00436-y. View

3.
Vallee A, Lecarpentier Y, Guillevin R, Vallee J . Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. Neurosci Bull. 2018; 34(3):573-588. PMC: 5960455. DOI: 10.1007/s12264-018-0219-5. View

4.
Hegi M, Diserens A, Godard S, Dietrich P, Regli L, Ostermann S . Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004; 10(6):1871-4. DOI: 10.1158/1078-0432.ccr-03-0384. View

5.
Yuan G, Niu L, Zhang Y, Wang X, Ma K, Yin H . Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. J Neurooncol. 2017; 133(1):193-201. DOI: 10.1007/s11060-017-2433-9. View